DEXIS to Showcase Cutting-Edge Innovations at IDS 2025
24.3.2025 09:00:00 CET | ACCESS Newswire | Press release
QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / March 24, 2025 / DEXIS, the global leader in dental imaging technologies, is excited to announce its participation in the International Dental Show (IDS) 2025 in Cologne, Germany.
The company will showcase new technologies within the DEXIS digital ecosystem, an AI-powered platform that connects each step of the digital workflow, from diagnosis to delivery. The ecosystem combines AI, 2D & 3D imaging, intraoral scanning, diagnostics, and treatment planning to create one integrated solution that streamlines processes and boosts productivity.
"We're excited to give IDS attendees the very first look at some of our new technologies," says DEXIS President, Robert Befidi. "All of our innovations are designed to improve patient interactions and make dental practices more effective and efficient. We're eager to put our products into the hands of dental professionals and demonstrate the capabilities of our new technologies."
Among these innovations are some exciting updates to the DEXIS intraoral scanning portfolio. Visitors will get an exclusive first look at the company's all-new intraoral scanner under development, Imprevo. With a sleek new design, fully rebuilt hardware, and AI-powered algorithm, Imprevo will become the new high-performance flagship of the DEXIS IOS portfolio.
IS ScanFlow, the software that powers the DEXIS intraoral scanner line, will preview its newest version, IS ScanFlow 2.0, featuring a new Smile Visualizer tool. The tool will allow dental professionals to show patients a realistic preview of their smile before and after treatments, helping them to visualize and better understand treatment recommendations.
DEXIS will also unveil updates to the ORTHOPANTOMOGRAPH™ OP 3D™ EX, which will soon include cephalometric imaging capabilities. The new ceph modality, which features the company's patented ORTHOceph™ Plus design, will provide necessary protocols such as lateral and pediatric lateral projections, posterior-anterior projections and carpus imaging* - all with fast scan times and at a limited dose.
Additionally, the DEXIS 3D imaging portfolio will introduce an Automatic Dose Control feature for the ORTHOPANTOMOGRAPH™ OP 3D™ LX. The feature will measure patients' anatomy and automatically set exposure levels for optimal image quality and dose. Early adopters have reported positive feedback:
"The new Automatic Dose Control is one of the few things in life I don't have to question," says Dr. Katya Archambault of San Diego Health Center. "It offers both better and more consistent image quality. I could never argue with the results."
Also being showcased are new features within DTX Studio™ Clinic, the core software of the DEXIS digital ecosystem. Known for its comprehensive integration of all modalities of patient data, DTX Studio Clinic streamlines diagnostics, patient education, treatment planning, and surgical guide generation.
The software's new features include a suite of tools designed to streamline the implant treatment planning process. Users can now plan an implant treatment and generate an automated surgical template chairside in under 3 minutes. Additionally, the software introduces an Assisted Implant Planning module that automates initial implant positioning, and a Face Scan tool that integrates facial scans with 3D X-rays, further enhancing the planning process.
Attendees will also get the chance to preview new innovations, set to be released in future updates of DTX Studio Clinic. Among these innovations is a new, AI-driven endodontic capability, that will provide 3D visualizations of root canals, enhancing diagnostic accuracy and treatment efficiency. Additionally, updates to the focus areas detection tool will be showcased, enhancing the visualization of teeth in intraoral X-rays and detecting eight additional dental findings.
DTX Studio Clinic will also introduce a new Cloud-based solution that will allow clinicians to connect their practices and consolidate data in one place. This feature is designed to enhance collaboration and streamline workflows, ultimately improving practice efficiency and patient outcomes. These advancements showcase the future of dental technology, making DTX Studio Clinic an integral part of modern dentistry.
DEXIS invites all IDS attendees to visit Hall 11.2 K050 L069 to experience the innovations that DEXIS has to offer. Their team of experts will be ready to provide demonstrations and answer questions.
With more than 165,000 solutions in use around the world, DEXIS continues to set the standard for quality and reliability in dental imaging. For more information about DEXIS and its participation in IDS, please visit DEXIS @ IDS 2025.
About DEXIS
DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit DEXIS.com.
About Envista
Envista Holdings Corporation is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
DXIS01006/Rev00
*Carpus is an optional imaging program
Contact Information
Maria Penaloza
Media & Content Strategy Manager
mariap@accessnewswire.com
Michelle Cabral
Senior Marketing Director, DEXIS
michelle.cabral@envistaco.com
SOURCE: Envista
View the original press release on ACCESS Newswire
Envista
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave11.8.2026 00:40:00 CEST | Press release
Reason for change: Unfinalized version was submitted Intends to grow the partnership to more than 650 megawatts (MW) over three phases First phase to deliver a complete turnkey data center solution with 222 MW beginning in the second half of 2027, representing approximately $6.5 billion in total contracted revenue Fermi and TensorWave have lined up world-class partners to collaborate on the project DALLAS, TX / ACCESS Newswire / August 10, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it has executed its first binding customer lease at its Project Matador campus in Carson County, Texas. The lease between Fermi's subsidiary Fermi Campus 1 LLC and TensorWave TEX1, LLC, a subsidiary of AI cloud provider TensorWave Inc., covers a facility supported by 222 megawatts (MW) of total facility power following commencement of the final delivery phase. Once fully delivered, the facility is being designed to support tens of t
Fermi Announces Binding Lease Agreement with TensorWave10.8.2026 23:10:00 CEST | Press release
Intends to grow the partnership to more than 650 megawatts (MW) over three phases First phase to deliver a complete turnkey data center solution with 222 MW beginning in the second half of 2027, representing approximately $6.5 billion in total contracted revenue Fermi and TensorWave have lined up world-class partners to collaborate on the project and expect certain of the obligations under the lease to be guaranteed by one of the global leaders in AI DALLAS, TX / ACCESS Newswire / August 10, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it has executed its first binding customer lease at its Project Matador campus in Carson County, Texas. The lease between Fermi's subsidiary Fermi Campus 1 LLC and TensorWave TEX1, LLC, a subsidiary of AI cloud provider TensorWave Inc., covers a facility supported by 222 megawatts (MW) of total facility power following commencement of the final delivery phase. Once fully delivered
Juno International Corporation Acquires Securities of Rocky Shore Gold Ltd.10.8.2026 23:10:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 10, 2026 / Juno International Corporation (formerly Northfield Capital Corporation) (the "Acquiror") announces that it acquired ownership and control of 1,549,000 common shares (the "Subject Shares") of Rocky Shore Gold Ltd. (the "Company") on July 24, 2026 through the facilities of the Canadian Securities Exchange, representing approximately 0.65% of all issued and outstanding common shares of the Company as of such date immediately following such transaction. Immediately before the transaction described above, the Acquiror held an aggregate of 40,569,188 common shares of the Company and common share purchase warrants entitling the Acquiror to acquire an additional 5,180,000 common shares of the Company (the "Warrants"), representing approximately 17.11% of the issued and outstanding common shares of the Company on a non-diluted basis (or approximately 18.88%, on a partially diluted basis, assuming exercise of the Warrants only). Upon completion
Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement10.8.2026 20:30:00 CEST | Press release
Not for distribution to United States newswire services or for dissemination in the United States. THUNDER BAY, ON / ACCESS Newswire / August 10, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) and Springbok Ventures Inc. ("Springbok") are pleased to announce that, further to the joint news release dated August 1, 2026, due to strong market demand they have agreed to increase the size of the previously announced non-brokered private placement of subscription receipts (the "Offering") to $6.1 million, as follows: 10,000,000 subscription receipts of Springbok (the "Springbok Subscription Receipts") at a price of $0.50 per Springbok Subscription Receipt; and 2,000,000 subscription receipts of Clean Air Metals (the CAM Subscription Receipts") at a price of $0.55 per CAM Subscription Receipt. Each Springbok Subscription Receipt will, subject to satisfaction or waiver of certain escrow release conditions, automatically convert in accordance with its terms
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom